Mayne Pharma Group Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported revenue was AUD 187.93 million compared to AUD 52.23 million a year ago. Net loss was AUD 70.55 million compared to net income of AUD 290.02 million a year ago.

Basic loss per share from continuing operations was AUD 0.878 compared to AUD 1.38 a year ago. Diluted loss per share from continuing operations was AUD 0.878 compared to AUD 1.38 a year ago. Basic loss per share was AUD 0.878 compared to basic earnings per share of AUD 3.52 a year ago.

Diluted loss per share was AUD 0.878 compared to diluted earnings per share of AUD 3.52 a year ago.